Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.c

Pericardial effusion (w/wo tamponade)

Publications

Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.

Drug safety. 2021;44(9):957-971

Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S

Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Cancer immunology, immunotherapy : CII. 2021;70(10):3041-3053

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL

Immune Checkpoint Inhibitor-Associated Pericarditis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019;14(6):1102-1108

Atallah-Yunes SA, Kadado AJ, Soe MH

Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.

Current problems in cancer. 2019;43(5):504-510

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

The Lancet. Oncology. 2018;19(12):1579-1589